Guggenheim names Surrozen top biotech stock following Johnson & Johnson acquisition announcement
SRZN Surrozen Inc
$31.74 +5.87%
View chart & analysis → - 1Johnson & Johnson is acquiring Olin Biosciences for an upfront payment of $2.2 billion.
- 2Guggenheim maintains a buy rating on Surrozen and sets a price target of $80.
- 3Surrozen recently expanded its Phase 2a clinical study scale.
So what's the key point?
Johnson & Johnson has decided to acquire Olin Biosciences. Guggenheim called Surrozen a top pick and expects its stock to reach $80.
Source Investing.com +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.